UPB Strangle Strategy
UPB (Upstream Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
UPB (Upstream Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $509.4M, a beta of 1.29 versus the broader market, a 52-week range of 7.25-33.68, average daily share volume of 997K, a public-listing history dating back to 2024, approximately 52 full-time employees. These structural characteristics shape how UPB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.29 places UPB roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on UPB?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current UPB snapshot
As of May 15, 2026, spot at $9.05, ATM IV 166.60%, IV rank 36.89%, expected move 47.76%. The strangle on UPB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on UPB specifically: UPB IV at 166.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 47.76% (roughly $4.32 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated UPB expiries trade a higher absolute premium for lower per-day decay. Position sizing on UPB should anchor to the underlying notional of $9.05 per share and to the trader's directional view on UPB stock.
UPB strangle setup
The UPB strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With UPB near $9.05, the first option leg uses a $9.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed UPB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 UPB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.50 | N/A |
| Buy 1 | Put | $8.60 | N/A |
UPB strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
UPB strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on UPB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on UPB
Strangles on UPB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the UPB chain.
UPB thesis for this strangle
The market-implied 1-standard-deviation range for UPB extends from approximately $4.73 on the downside to $13.37 on the upside. A UPB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current UPB IV rank near 36.89% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on UPB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, UPB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to UPB-specific events.
UPB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. UPB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move UPB alongside the broader basket even when UPB-specific fundamentals are unchanged. Always rebuild the position from current UPB chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on UPB?
- A strangle on UPB is the strangle strategy applied to UPB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With UPB stock trading near $9.05, the strikes shown on this page are snapped to the nearest listed UPB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are UPB strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the UPB strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 166.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a UPB strangle?
- The breakeven for the UPB strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current UPB market-implied 1-standard-deviation expected move is approximately 47.76%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on UPB?
- Strangles on UPB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the UPB chain.
- How does current UPB implied volatility affect this strangle?
- UPB ATM IV is at 166.60% with IV rank near 36.89%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.